Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Table 3

Analysis of predictors of OS.

Variable	Kaplan–Meier analysis			Cox multivariate regression analysis
	HR	95% CI		HR	95% CI
Age	0.86	0.51–1.44	0.56
Sex	0.78	0.41–1.46	0.46
ECOG PS	1.04	0.51–2.09	0.92
BMI	0.91	0.54–1.54	0.73
Smoking	1.21	0.72–2.02	0.47
Distant metastasis	0.69	0.40–1.19	0.16
Treatment lines	0.97	0.53–1.79	0.86
Bone metastasis	0.60	0.26–1.35	0.13
Treatment regimen (anti-PD-1/PD-L1)	2.55	1.05–6.20	0.003	2.31	1.17–4.56	0.016
PLR (cutoff = 206.5)	1.84	1.09–3.10	0.032	2.12	1.08–4.15	0.028
LDH (cutoff = 194.5 U/L)	3.24	1.81–5.81	0.004	2.65	1.08–6.52	0.034
AMC (cutoff = 0.62 × 10^9/L)	2.26	0.90–5.70	0.015	3.98	1.83–8.65	0.0005

Indicators with statistical significance; —Represents no usability data; AMC, absolute monocyte count; LDH, lactate dehydrogenase; PLR, plateletlymphocyte ratio; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand-1; BMI, body mass index.